Another aspect, a negative correlation was found in MYBL1 with ips_CTLA4_pos_PD1_neg and ips_CTLA4_neg_PD1_pos, indicating that MYBL1 could affect the immunotherapy response of ccRCC patients (Figures 5E–H). Here, MYBL1 is linked to nonpapillary renal cell carcinoma.